TMDX - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to TransMedics' First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I would now like to turn the call over to Lynn Lewis from the Gilmartin Group for a few introductory comments.

Lynn Lewis

Thank you. Earlier today TransMedics released financial results for the quarter ended March 31, 2021. press available the website. the of copy release on is company's A

forward-looking future approvals uncertainties revenue, actual this statements of are anticipated we statements, the based remind made opportunity the this Securities operating to and our forward-looking include to statements forward-looking to expectations risks financial not I'd pursuant for XXXX relate call the that Reform of include statements for Act which gross expenses that Before involve are Harbor products like These Private make on material guidance are place to in current you and the limitation, begin, provisions XXXX. which securities Litigation federal without laws, potential performance predictions by undue management our implied including, Any Safe or will expectations, that events, future within and differ cause and/or are that Accordingly, expectations reimbursement, materially forward-looking margins of reliance these and meaning and various you of could statements. examination statements. organization, call and statements. trends, or statements All contained for in growth should operating results or of events commercial or estimates from our regulatory assumptions. upon these expectations results in those our during

except today, revise time Commission update by Waleed Annual over now forward-looking uncertainties on on the Exchange required TransMedics Officer. and Factors with of and financial to broadcast Chief information Hassanein, information, because of associated our sensitive X, with our conference the Executive statements a For and the law, contains call or or future any call description XXXX. intention to events, turn XXXX. filed XX, Securities Form refer any and the Report that, new risks accurate live is Risk obligation, disclaims business, I'll with list as or section March of May as And XX-K and otherwise. please This only or of President projections whether to

Waleed Hassanein

Lynn, sorry, difficulties earlier. everyone the first technical Thank TransMedics quarter Good everyone, and for call. earnings XXXX very to welcome you much, and afternoon the

today our Chief Gordon, is me Joining Stephen Officer. Financial

year. stated we catalysts last The we our XXXX, looking As strong for first the this will covering X the to to expecting was long-term we call, be call. growth several set in be catalyst believe Today I positive in we're on vote and are topics our FDA many foundation year Heart indication TransMedics. PMA this following major approve for panel throughout DBD which forward achieved will important a to more our

the a summary of results quarter. our First, financial for

the achieved progress strategic across initiatives. Second, our key

on a was update the I discuss Third, results. for Heart catalysts commentary impact their meeting business. first XXXX expectations panel OCS Fourth, remainder status the and $X.X the on upcoming Net revenue the XXXX. then topic. Starting potential finally, will of million. with for our first in quarter on our And

recognize that to U.S. despite Liver, revenue OCS contribution X% our minimal CAP important completion the the from year-over-year, overall to it grew our While business roughly of is enrollment. declined XX% due

the hospitals. impact activities. the business the overall due encouraged O-U.S. continued U.S. in European by are our U.S. transplant the continued on and numbers COVID the the in to throughout recovery We growth disruptions struggle transplant to revenues and

and topic second operational TransMedics. strategic the progress XXXX we drive laser our for initiatives me to across first outlined quarter, business, to initiatives made to focused all the for key major our are which we In discuss. on leads meaningful help growth We for strategic

of status Program. by describing National start OCS the me Let the

benefits and among awareness North regions activities in bringing to our are U.S. in reach Carolina we States, increasing the transplant and throughout new clinical In national the expand about while we We as in key United regions financial stakeholders. X Arizona, continuing initiated this initiated program total leverage expanded the X its build QX, and and clinical to

with stated engaged regions OPOs goal new actively active are in XX meet being our to of several by We year-end.

X transplant market U.S., We webinars programs also targeting held the Program. OCS lung National across this to

of of program. these We and continuing broader any Meanwhile the will necessary infrastructure hurdles build long-term webinars awareness continue potential to we're resources year ensure hold to the for to maximize throughout and the address this approach. success important adoption to this

clinical this as add expect and XXXX and throughout capabilities continue additional to we indications. new into XXXX, We early service and organs new

the OCS utilization believe States. previously, an in long-term we be the growth revenue important As that strongly mid- stated and and National will program OCS for we driver United

Liver Moving our panel this OCS to FDA the PMA. second on to our forward been with engaged OCS we initiative, important look advisory We've in PMA actively holding and mid-July. Liver now

Liver panel the of of of Given OCS the the FDA is approving CAP. date, the tranche proximity the now the second questioning timing

to discussing panel FDA a resolution soon. is hope one really where We set bitter-sweet thrilled are date with This have reach issue to QX. are the this and we a in actively situation, in hand

seems in in current before QX. and increases year-end. impacting said, associated benefit will and it focus the its approval timing to be That which confidence on the revenue our success, panel However, been potential negatively from the approval long-term remains has CAP always that

DCD the Our third indication. was OCS Heart strategic advancing initiative

As randomized enrolled XXX track additional system on heart on protocol. access heart of line OCS important XXXX. end transplant XXX-patient the DCD we top heart those new on We program OCS. using specifically we've cases completed readout the Heart were QX using with for continued in in this of patients At in DCD have QX, DCD trial DCD for X, the OCS April XXXX, remain you of XX our transplanted know, XX

important of panel was Heart DBD We with approval Finally, our for the a strong indication. this OCS initiative fourth favorable milestone strategic Heart PMA. finally vote the completed DBD OCS

few me from this XXXX. panel the to opportunity the clarify topic allow meeting. are turning third approval Please and Now focused decision on we success major an into this cover observations discuss in and

theme a the discussions key surprise and expected panel were were a fully not of for TransMedics. First,

FDA. were topic we address Importantly, by to prepared raised major every

panelists comments controversial seems with or the experience. from heart came transplant that of no many Second, limited

as So the ultimate may not be one relevant as would impact think.

to that believe label, label support an clinical the Heart we from CAP the approved related and appropriate the DBD data, for the FDA. OCS evidence expand Third, if by indication,

in remember of must language we in nature the that OCS multiple and PMAs organ the given static label concurrent never same Importantly, the they typically transplant fluid are market. evolved are our indications our

study to XXXX Heart For post-approval order and real our our updated evidence with have position. I'm continue the sorry be enable the approval Heart which language example, with for XXXX world the DBD will indication label results in of in proposed post-approval -- in study, to of a to DCD Fourth, we expansion and indication. build market our indications, setting to potential leading in support the the the

a by academic that to to and cardiologists post-approval design robust leading U.S. practical We failure is and easy surgeons heart supported are study implement.

Finally, I'd an conducted System. the program like animal studies safety of reiterate to pre-clinical of XXs TransMedics extensive supporting and that with the clarify testing OCS Heart

have human globe, DBD results. we hearts Importantly, clinical transplanted to with we DCD donors need across remember the more than excellent and both from human X,XXX that

on I would Now to for catalysts major topic update XXXX. our to like X provide move status let me fourth major that and cover the

overall want trajectory growth on future. I potential impact highlight for Importantly, of the the to these our foreseeable catalysts

FDA DBD is The of we Heart approval catalyst expect the indication. first OCS

FDA the engaged course. Heart, drive we FDA In preparation a of actively next commercial the approval the to months. hopefully are are OCS launch with the few regulatory of We pending parallel, to decision continuing over for the

XX clinical the our with engaged heart that currently given are program. with Heart we the their DCD experience OCS the are active in in Specifically, transplant program, CAP centers DCD

robust We we and are FDA program national the add approval is active infrastructure practical to the enhanced. finally, post approval that implement KOLs design registry regions to working preparing Heart are to to with in to once scale. planning our in and is And our leverage our we're OCS to OCS the a

The is and meeting OCS second panel potential FDA catalyst the approval. subsequent Liver

forward and we're to position this well mid-July, approval to Heart, in XXXX. XXXX. the OCS engaged Liver which in potential the conducting QX Similar prepare later in We the OCS in early meeting Liver our actively as a presented national centers our to once another for are approval enhanced. program OCS to launch On U.S. panel would a presentation OCS with FDA us for is Congress potential will regions also session June. PROTECT OCS our Trial in full results upcoming add the be Liver up Transplant to We're plenary with note, approval planning at follow X-year looking American

exact the and the is announce date program We finalized. once time will

milestone. approval OCS This that The National it third filed coverage potential FDA of we been fourth to the XXXX. and in are U.S. in is The is we indication its Heart for and OCS under catalyst will be has of track will optimistic DCD breakthrough PMA potential and we data This and line the of and XX designation on from heart the least the expanding that supplement. expansion support XXXX targeted believe the this QX liver. major at filing regions cover achieve read-out Program are to the for the top clinical catalyst

is of track The the and on year-end. impact potential journals. in data and clinical OCS on the are OCS and OCS the publications Again, We a adoption of Liver meet achieve to driver will fifth broader clinical track These standard DBD are to high a care publication trial by globally. and the medical DCD critical milestone. final be this this we for the transformation catalyst technology milestone of

remain a near pronounced volumes. expectations and we XXXX. COVID term. variants new Europe, the finish transplant in impact terms remainder a see of and normalization specifically this and me the transplant summary with activities internationally in its threat to let of of our for Now more in thoughts Today,

lung activities being volume recover final So continue to to far, from U.S. perspective. recover with organ transplant the

at last to still, anywhere QX, X% in are We below between year's X% least volumes.

any in United revenue OCS hope the major emerging these our Liver FDA and and on decision as to view barring Heart leverage our from programs timelines OCS new would this continue the expect in We peak to ability regulatory grow States. limiting for that near We programs. potentially CAP recovery the term

be U.S. to expect late in in XXXX major catalyst the a we However, drive growth and revenue approvals beyond. to

indications the a to Specifically, all Liver panel approved goal impact our with fundamental growth CAP will revenue trajectory QX. FDA, driver on hesitation due second the approval XXXX remain to transplant from major be our Liver on huge ending We CAP by tranche imminent revenue our and however, in X the streamline for which generate future. may date revenue laser-focused, FDAs ability of the for negatively

Chief guidance the financial quarter turn Stephen Given issue Gordon, to for the and to key XXXX. for that, call detailed current Officer, the imminent financial our not results With uncertainties year. timelines, the we review FDA will Financial I and will our full

Stephen Gordon

financial other and now you, Waleed. would detail on provide the results for I the additional information quarter. Thank some QX

quarter first the was million. gross For revenue of net by revenue million revenue from the and $X.X first X% was Net $X.X XXXX. of XXXX, decreased quarter

U.S., million million of Lung, of the U.S. and increased OCS the and breakdown $X.X gross net million OCS was first was revenue The organ in million $X.X and net $X.X $X.X XX% However, was revenue Liver. U.S. quarter net from million of on Heart revenue revenue OCS $X XXXX. of

strong included of up for Our the $X.X for OCS last compared million, line million reflecting QX which million, and continued transplant the activity. QX the a margin Heart. of Liver $X.X activity of quarter OCS transplant in to $X.X million with expenses Gross and ex-U.S. of revenue XXXX Lung of the from were was from Heart U.S. our XX% first XX% year performance U.S., and outside quarter. the driver fourth OCS But of was $X of OCS The expectation key margin. quarter QX XXXX. revenue QX of and XX% million XXXX quarter and in and last was were was completion $XX.X lower increasing in X% from OCS XXXX the CAP of stated Lung PROTECT XX% the Total the sales gross quarter, up headwinds down in and for U.S. the recovery operating

our due to spending are our still spending, invest national impacting other program. continued growing and have OCS travel limited we to COVID in While

million million the quarter million the in in for loss compared quarter the $X.X million XXXX XXXX. was $X $X.X quarter of $X.X was XXXX net to first quarter to compared loss of in the of operating first Our of first and first XXXX our

And reduction confirming, common were we quarter March $XX.X average weighted these were just to shares end as for the from and the at XXXX equivalents to this securities current while comments XX, are And XXXX. balance cash providing outstanding are guidance due not for time. uncertainty, million. million cash, a XXXX, million at $XXX.X equates Finally, of which of $X.X the of marketable

Now like to to comments. Waleed the I would for turn closing call back

Waleed Hassanein

you, Thank Stephen.

are cadence XXXX. FDA prospects, across continue near term confident catalyst of review the all While clinical revenue and in is expected and the growth timelines, in given progress our we by trials long-term impacted to be our to optimistic in

the that U.S. and we platform. With organ I'm confident are our field now XXXX business major to as end excited for in operator that, the remains our on and long with of Q&A. Heart this We transplant our X towards in market remain Liver ultimate commercial advancing in is fundamentally OCS transform we transplantation the trajectory we decisions indications OCS I'll our using ramifications indications term. alter approved Operator? The regulatory have that growth will the that and and X confident goal rapidly globally of OCS turn our technology about goal significant will future call attainable. continue to the business

Operator

Instructions]. [Operator

question first Robbie line of the from comes Marcus from Your JPMorgan.

Unidentified Analyst

for [ph] You've here got Farhan Robbie. on

on understand potentially of of heart terms understood it get about panel expanded commentary your me What's from additional better. look you what like and label mentioned outcome the a you need panel, in help trial the or to expect happen to there, the firstly, the to when what the your little I but So sense you criteria.

of talk me help kind puts Just takes and the some through of here.

Waleed Hassanein

that the the criteria. trial extended I the criteria The label us come EXPAND panel trials that additional We we program will point, That's of a to referring we confident to be along. of cover for get don't FDA the to is studied I label about registry. very this was able the We all don't to that. feel help expanded proposed will part do have the our at that post-market post-approval expect Trial. think -- this we to in out all

of should the So clarify. we hearts thinking all able are want to were Trial. the expanded The be I criteria studied speaking in to that about label just cover and EXPAND

Unidentified Analyst

then some of seen know Is in here? something demand commercial And pent-up you've you you. work Thank to med quarter switching franchise tech? the do I the and Lung. to are through going great. backlog some you've some the Okay, recoveries been seeing previous What you seen saw Have and the through. lung from quarter? you that broader in this what progressing in expect dynamics forward

Waleed Hassanein

to and organs, long get see to still but coming We recently lagging out expect is another COVID the the The we continue recover. Lung patients COVID. there close we've as to transplanted being as don't suffering thing with of peak. to and It's after continue it's expect they've X are been we that more transparently more recovery that noticing more been

that from acute lung to patient COVID because the and a COVID function. list coming in lung completely up destroying and an the suffered profiles transplant transplant getting are Younger ended situation they had waiting

that's stay another we for witnessed we younger lung thing that that on the with lung had could traditional QX. pent-up eyes something COVID our that wave year. could keeping us that's only failure term. coming patients, not because So -- patients that patients, new last that's demand But are -- in more they our the create because are long dynamic only transplant More of and

Operator

Your line next comes from Morgan Furlong question Cecilia of from Stanley. the

Cecilia Furlong

QX, extent, I just more start in about wanted talk the model. the guess certain seen with disrupted you've pathway. Could I of traction to a kind bit little COVID service to you

CAP in from about what now the of then the hard how for a model? right service service between centers proposition COVID commercialization model. you moving And the out value active that the just thinking into versus just guess I So world roll Heart, recovering in you're

Waleed Hassanein

Sure.

stated as about before, the national So we this excited we're the are to first -- we program. program, one relating

a going of to sort impact-wise, long-term have the and we economically, think clinically, impact, even significant our adoption done this -- are transplant proposition, the lung on mid the we have program financially and value programs. COVID-related balance-wise disseminated work-life What broadly of to technology. and in is is both We QX all

starting build. traction to seeing the are We

there anything, and I'm COVID from to continue a towards to. to of take have the end traction going We what a bit QX momentum the expect build little wanted program. longer palpable than given generated QX. really that If everything to year is that is environment, into this this to is looking we Really,

have building yes, the envision with We only add that DCD of proposition first. the provide those we understand we given an least continue have early where We program, to Heart national whether need to need one to OCS revenue. as to XX reiterate to that flexible the build. same or see to the the XXXX that value value And them was be path. we commercialization, Heart we're -- momentum Cecilia, -- will win both OCS, us active QX starting our hopefully for now next the and hopefully top mechanisms they to in to whether then active program, the the of national on focus been fact start that, up patient trying Relating CAP and our expand flexible and to and or themselves So tangible we'll we going technology the for to the that be DCD, adoption the throughout in programs way. that an throughout even the and that to of they quarters declare proposition of but momentum reflected the with experience follow into continue We with direct will ourselves layer or program. by -- mid-XXXX year-end continue commercialization, acquisition at X and through evidence see to X Liver with through have

want early to don't be the we adoption the We we're times think So this disrupt several stated than to curve staying before. both all for different But we reasons mechanisms enabling going Lung on. to We're drive is adoption. flexible. that

Cecilia Furlong

and to just tranche And on quarter, what could the just seeing quarter hear first a I you panel? saw you're the timeframe as about on standpoint. kind at bit you clarity heart COVID just and we listed cadence headwinds then, just and through a trends to could the of from the DCD progress if on performance guess of Liver just And really talk well, you the when end in or go just second more OCS into as the April this

Waleed Hassanein

Sure.

us enrollment program -- numbers in excitement One, past. more confidence gives So for we're we're very high that DCD -- in no we've the compared even concentrated in conducted no and more we've X longer the on limiting focused any all-time leading the or But not top of X what limited program to longer or that hands of the Heart bullish is still the pace the we're centers. at reasons. X enrollment QX or or is seen now we're

would last those, at a or macro or level, hearts to we which U.S. Now number XX really -- been because transplants hearts you transplanted. basis. would These OCS QX that total there we approximately for seeing the in deep as broadly track And very in in is are of look to compared XX cases medium distribution programs, not impact doing a of really volume. when meaningfully were have this the hearts. into additional the year centers they exciting their on QX. a heart new And DCD across centers, otherwise were that Of was are sort XX transplant XX that us. XX we're In of are quarterly QX, seeing quite new enrollment volume

QX. So transplant approximately in XX% XX% the heart of growth or OCS contributed of the to

So that's for very us. exciting

it I and -- CAP, to we really Heart the to on this front. expect to expect hope we Cecilia this continue close very We think we're here. cutting Relating Liver the trajectory

but will And look the that our probably the doing it convince sort perspective, to are scheduled you time important, is by approval, best, FDA mid-July. the it We we at also CAP early their of the panel from when June, trying in mid-June. get be

approval very we're have or would be not during drive just CAP QX clear will these going and in or we through the the it drive there. think to whether from a I just tranche panel second So

XX days or hopefully, that visibility have So the so. we'll with next

Operator

next comes Jennings Josh of Your from from line question the Cowen.

Unidentified Analyst

to your Brian comment wanted Josh. here with I for clarification just start on Liver on CAP. a the

you've activity safety don't of the concerns But outweigh the understand that very approvals priority data favorable gotten about is or clearly not seen I terms increasing the So we've CAP, any CapEx for what rationale the the and in the specifically the efficacy? given raise company. view for that

Waleed Hassanein

very, Brian, panel that's very, comment close get feedback an high-level question. very go approval. specifically. we we're so is to a and Unfortunately, -- I that through the just can't we one received panel, excellent But the at very,

concern. of So prevail we some will hope we're see going and see we but there where next is nothing gives completely the and we there aware days. with are sentiment, we XX they're with wait pause the very arguments we in it, back coming data but see of highlighted you that we from and any so, is agree we'll The us that your But also -- or that strong.

how We are we also are, by as understand but that as feedback the you for timeline are to the panel. we close confused

Unidentified Analyst

changing you the to of Can months. you see next and maybe O-U.S. the month gears getting progression And the over of of experienced you've couple month same whether sort that better share the staying trends or just just recently to

Stephen Gordon

Yes. Brian, Stephen. this is

back where international where are was It's in are definitely and slow seeing think at from of are steady. So the we a it QX. kind look yet, April, seeing if trend in you some that early in it's I we come we don't the business. definitely uptick but

Operator

of Plovanic Next from the comes Bill question line Canaccord. from

William Plovanic

questions. Two

is clarification audits gain Do the on Heart approval. to any remaining approval? that you Just have first FDA

Waleed Hassanein

all passed audits with No, back. flying we a colors while the

William Plovanic

the completed pushed for in then discussion the in Okay. for the label, discussions? post-approval approval on Where on those terms you same question that study? and the you are in And then label of discussion have

Waleed Hassanein

Right.

the the decision these making at that's the a waiting two we No, point few so them label final that is -- and focused final profits PAS are questions. waiting is for. -- we're on decision the things are and that remaining design made, that Bill, language, this on So great once the

William Plovanic

you a a Would expected on they that decision have then Or labeling before frame? do frame? And have at you PAS? Okay. provided move the final of time you time to have kind

Waleed Hassanein

I months time that is are these pre-panel, from date, with communicated which to overall the the panel -- same frame time the hold are same and frames will given X our believe time that recent think the frames we've X I discussions FDA.

William Plovanic

And more prepared a was yes, want confirm back if going they approval. in you we're to animal just, I any to can, regulatory just or anything and your Okay. marks testing know do it that to go not ask of -- even as don't required that I but nature

Waleed Hassanein

I can.

the listen, of animals cannot date of Bill, the submitted. were animal was FDA I of data closing So, there's the There My data hundreds going remarks -- I on for. tens predict here. a mischaracterization ask significant is and are really what remarks made is that to to panel

results For that's the to some date, to all panel access raised reason, the it all was was panel the that not data at reflected discussion, address us this what in question we the and gives the confidence. have and

So the that's of aspect answer. one

The of as always answer the second over aspect prioritize testing. any FDA data the you human know, all is, preclinical

feel given very FDA. feel with correct, questions across, to data can mischaracterization, that not in or preclinical the really to. significant the whatever was that by misunderstanding in of get that date at the remark have we was that access the that given the found And that we accurate remaining our trying So was PMA. position number program, help with and/or any animal that or presented I the our very fact our studies this And were comment confident submitted and or preclinical the clarify open we we confident data statement would address

William Plovanic

second on then That's program. OPO Thanks. Okay. really the And just is helpful. question

getting those You for, the provided of seeing X, really do podiatry. a second their of what maybe you're to of and speaking. you're is? of I sites but or they kind what has just that X, once for tripled? just feeling traction. just done it's for Has up to first of looking kind the appreciate color what they timing doubled that to I first are for get around doing? the going? kind can that more signed X in now players? I'm Have any signed up, what you this get trying kind this business? Or just And okay, they're a I'm what this terms expanded -- site first up it

Waleed Hassanein

Sure.

I think, question. a that's great Bill,

of own I I can to various you did share what loans their think think X the program. of older joining assure X following: seen seen the the meaning transfected. X, that four, do otherwise the I because X of their that OCS with X. cases publicly But that just obviously, the them or X say, OPO And would those X transplanted. do in cases, is of own value out business I what can OCS di X in can another with sphere, have get did vintage of of the never have the really would out I of X magnitude, more have X value the the OPO

yet -- X value of -- the successful the given OCS, its other hasn't the are a recent -- OPOs taking with. one. remaining And case seen of weren't in working the this but One X new one it, new hasn't transplant, it it materialized it that just the -- to Lungs was we're but most to materialized is see have has two seen because

in, OPOs allow the way the to year-end. massive this by and even allow really this. that see begin that a I'm need into we hopefully to can results protect report mass to now, critical expect to that more OPOs, program, how critical XXXX, where trend maybe mature it a to we about year-end time can to continue. And have we track it forward we right that's targeting But and so I attract can going So why be aggregation and involved we're going

Operator

Your Kalia next line question from Suraj from of comes the Oppenheimer.

Suraj Kalia

So questions. few Waleed, a

Let storage, me superiority for it's to there analysis remind is non-inferiority start me, out with the hierarchical trial, DCD right? relative no trial. cold a and Waleed,

Waleed Hassanein

is This Raj. so, a Not DCD trial.

And right? bananas, hearts. meaning comparing storage apples cold we're and standard plicera So

are design the was been not otherwise parts have highly I here. these It's So would would that transplanted. because unlikely, stop always

design. see We the it doing for wait another you that's a the the an based the is I'll is, the I -- is that -- trial. have of and or we on for what this So indication, we randomized to design and exact don't result actually when to the answer we off-line protocol. a validity But test superiority questioned with have remember, what that. which our Suraj, we not. trial I but have superiority, don't Usually, expectations is testing we the you for I follow-up answer if to [indiscernible] need give shows.

Suraj Kalia

Waleed, in on filed data just the us was the liver. XXXX. terms line, through, And something top this me -- if of have in you of top seen below I liver, wondering panel, data walk So the heart is if on was up correct the wrong, I'm QX the we line could following PMA

for FDA been on looking Is the for in hiccup a has a your time. FDA that this again So could be at Liver the data something view side? period this long of

Waleed Hassanein

any strongly and following: clinical history of statistical could what statistical number rate endpoints the is described. we But conducted. I implementation be their of hiccup we've cleanest. is It's conducted the from that of It's the application. predict pick assert something could that the trial liver the FDA we've is All very FDA sure that cannot for a Liver feel highest an the a superiority in our we've from just data trial achieved TransMedics. is what on I in any perspective, I'm perspective, achieving the our I ever relevant. endpoints data cleanest, Suraj, superiority on can of highest in any

Suraj Kalia

final once the practical trying assessment in hop approval and you panel, panel, Post question, heart? a and centers do just panel, I'm the one many DBD you'll centers the in heart U.S. queue. Waleed, O-U.S. to And the in to back are in the getting I'll Post get heart from heart the expect how of the add feedback you new ground. get

Waleed Hassanein

fruit. X the anywhere XX expand sort that XX be think targeting of in launching sites, to we're low heart CAP. approval are is FDA between are the I we in sites. hanging the hand, XX DCD involving think our I plus These heart That would once

Operator

Okay. time. back to closing question for remarks. I any over this don't any see I turn will it Waleed at

Waleed Hassanein

for Have wonderful joining call. our you, Thank afternoon. look Thank to you, and on this Bye-bye. call, everybody, us next forward a operator. we

Operator

conference today's you for participating. call. concludes This Thank

disconnect. now may You

TransMedics (TMDX) 5 May 212021 Q1 Earnings call transcript